Document Detail


Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding.
MedLine Citation:
PMID:  23188028     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONTEXT: The need for anticoagulation after surgical aortic valve replacement (AVR) with biological prostheses is not well examined.
OBJECTIVE: To perform a nationwide study of the association of warfarin treatment with the risk of thromboembolic complications, bleeding incidents, and cardiovascular deaths after bioprosthetic AVR surgery.
DESIGN, SETTING, AND PARTICIPANTS: Through a search in the Danish National Patient Registry, 4075 patients were identified who had bioprosthetic AVR surgery performed between January 1, 1997, and December 31, 2009. Concomitant comorbidity and medication were retrieved. Poisson regression models were used to determine risk.
MAIN OUTCOME MEASURES: Incidence rate ratios (IRRs) of strokes, thromboembolic events, cardiovascular deaths, and bleeding incidents by discontinuing warfarin as opposed to continued treatment 30 to 89 days, 90 to 179 days, 180 to 364 days, 365 to 729 days, and at least 730 days after surgery.
RESULTS: The median duration of follow-up was 6.57 person-years. Estimated rates of events per 100 person-years in patients not treated with warfarin compared with those treated with warfarin with comparative absolute risk were 7.00 (95% CI, 4.07-12.06) vs 2.69 (95% CI, 1.49-4.87; adjusted IRR, 2.46; 95% CI, 1.09-5.55) for strokes; 13.07 (95% CI, 8.76-19.50) vs 3.97 (95% CI, 2.43-6.48; adjusted IRR, 2.93; 95% CI, 1.54-5.55) for thromboembolic events; 11.86 (95% CI, 7.81-18.01) vs 5.37 (95% CI, 3.54-8.16; adjusted IRR, 2.32; 95% CI, 1.28-4.22) for bleeding incidents; and 31.74 (95% CI, 24.69-40.79) vs 3.83 (95% CI, 2.35-6.25; adjusted IRR, 7.61; 95% CI, 4.37-13.26) for cardiovascular deaths within 30 to 89 days after surgery; and 6.50 (95% CI, 4.67-9.06) vs 2.08 (95% CI, 0.99-4.36; adjusted IRR, 3.51; 95% CI, 1.54-8.03) for cardiovascular deaths within 90 to 179 days after surgery.
CONCLUSION: Discontinuation of warfarin treatment within 6 months after bioprosthetic AVR surgery was associated with increased cardiovascular death.
Authors:
Charlotte Mérie; Lars Køber; Peter Skov Olsen; Charlotte Andersson; Gunnar Gislason; Jan Skov Jensen; Christian Torp-Pedersen
Related Documents :
8179948 - British family heart study: its design and method, and prevalence of cardiovascular ris...
24091838 - Musculoskeletal symptoms and psychosocial work environment, among swedish commercial pi...
9355888 - Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction.
2321628 - Total and hdl cholesterol and their correlates in elderly men in finland, italy, and th...
22523018 - 100-point scale evaluating job satisfaction and the results of the 12-item general heal...
17667648 - Smoking and myocardial infarction case-fatality: hospital and population approach.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  JAMA     Volume:  308     ISSN:  1538-3598     ISO Abbreviation:  JAMA     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-28     Completed Date:  2012-12-03     Revised Date:  2014-09-17    
Medline Journal Info:
Nlm Unique ID:  7501160     Medline TA:  JAMA     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2118-25     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Anticoagulants / administration & dosage*
Aortic Valve / surgery
Cardiovascular Diseases / mortality*
Denmark / epidemiology
Drug Administration Schedule
Female
Follow-Up Studies
Heart Defects, Congenital / surgery*
Heart Valve Diseases / surgery*
Heart Valve Prosthesis Implantation*
Hemorrhage / epidemiology*
Humans
Incidence
Male
Middle Aged
Registries / statistics & numerical data
Risk
Stroke / epidemiology
Thromboembolism / epidemiology*
Warfarin / administration & dosage*
Chemical
Reg. No./Substance:
0/Anticoagulants; 5Q7ZVV76EI/Warfarin
Comments/Corrections
Comment In:
JAMA. 2013 Mar 27;309(12):1225   [PMID:  23532228 ]
JAMA. 2013 Mar 27;309(12):1225-6   [PMID:  23532229 ]
JAMA. 2012 Nov 28;308(20):2147-8   [PMID:  23188033 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Association between use of renin-angiotensin system antagonists and mortality in patients with heart...
Next Document:  Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last v...